Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
NCT03409432Phase 2Completed
- Start
- Mar 2018
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, lenalidomide in T-cell lymphoma. Started Mar 2018; status: completed.
02
Drugs
brentuximab vedotinlenalidomide
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT03409432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409432.